Trials / Completed
CompletedNCT00002130
A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Otsuka America Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To examine the continued safety and tolerability of four doses of vesnarinone in HIV-infected patients who have completed a short-term study (less than 12 months on continuous treatment) of the drug.
Detailed description
Patients who have completed a limited duration study (less than 12 months of continuous treatment) of vesnarinone on protocols FDA 234A or FDA 234B and who have no current signs or symptoms of AIDS-defining illnesses may roll over to this study and continue receiving their regimen of vesnarinone for 12 months beyond their original participation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vesnarinone |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002130. Inclusion in this directory is not an endorsement.